Glenmark Pharmaceuticals has reported a total income of Rs.3023.54 crores during the period ended June 30, 2021, as compared to Rs.2403.30 crores during the corresponding period last fiscal. The total income for the period ended March 31, 2021, stood at Rs 2,868.39 crores.

The company has posted a net profit of Rs.306.52 crores for the period ended June 30, 2021, as against a net profit of Rs.254.04 crores for the corresponding period last fiscal. The net profit for the period ended March 31, 2021, stood at Rs 233.87 crores.

The company has reported EPS of Rs.10.86 for the period ended June 30, 2021, as compared to Rs 9 for the corresponding period last fiscal. The EPS for the period ended March 31, 2021, stood at Rs 8.29.

“It was a landmark quarter for the company with positive momentum in all our key markets. Our commitment towards the fight against COVID19 was reflected in FabiFlu becoming the number one brand in the Indian pharma market in April. We launched our first nebulizer, Arformoterol Inhalation solution from Monroe, US.” said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals.

He further added, “We have a strategic roadmap to grow consistently and profitably over the year. “We have a clear plan in place to reduce debt by enhancing free cash, prioritizing over R&D investments and capital expenditure going forward.”